BridgeBio Pharma(BBIO)今日盘前股价大涨9.61%，引发市场关注。这一涨幅主要源于公司发布的第一季度财报超出市场预期，特别是其心脏病药物Attruby的销售表现出色。
根据公司公布的财报，BridgeBio第一季度调整后每股亏损为0.88美元，好于分析师预期的0.92美元亏损。公司营收达到1.1663亿美元，远高于分析师预期的6194万美元。其中，Attruby在第一季度的销售额达到3670万美元，大幅超过市场预期的1310万美元。
Attruby是BridgeBio用于治疗成人转甲状腺素淀粉样心肌病(ATTR-CM)的药物，自2024年11月获得FDA批准以来表现强劲。截至4月25日，已有756家医疗机构为2072名患者开具了Attruby处方。分析师普遍看好BridgeBio的前景，给予"买入"评级，并将12个月目标价中位数设定在53美元。这些积极因素共同推动了公司股价的大幅上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.